SCHEMBL2635974

SCHEMBL2635974

CN(C)CCNC(=O)COc1ccccc1NC(=O)COc1cc(C(=O)O)cc2cc(Cl)cc(Cl)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
POLB P06746 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
TRPM4 Q8TD43 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK10 P53779 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
NOD2 Q9HC29 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636416 0.91 POLB (0.47) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2635787 0.89 LMNA (0.49) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2636138 0.89 POLB (0.45) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2636709 0.87 POLB (0.48) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2636056 0.86 POLB (0.51) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2635491 0.86 POLB (0.53) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2636273 0.85 NPC1 (0.56) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL2635583 0.84 POLB (0.51) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2640776 0.83 POLB (0.46) LMNAPOLBNPC1RAB9AMEN1
SCHEMBL2635896 0.82 POLB (0.48) LMNAPOLBNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US claimed
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 LMNA 1894/4885POLB 2948/4885NPC1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.